A Retrospective Real-World Analysis of Serdexmethylphenidate/dexmethylphenidate for Patients With Attention-Deficit Hyperactivity Disorder
Aim: To assess treatment patterns in patients with attention-deficit hyperactivity disorder (ADHD) treated with serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) or comparators using real-world data from a large-scale claims database.
Methods: Retrospective analyses were performed on data from open and closed insurance claims spanning January 2020–August 2023, evaluating demographics, treatment patterns, and SDX/d-MPH use in ADHD. Included were patients with an ADHD diagnosis receiving SDX/d-MPH or branded or generic comparators (lisdexamfetamine, amphetamine, amphetamine/dextroamphetamine extended release [XR], dexmethylphenidate, methylphenidate, and XR viloxazine). Patients continuously enrolled in a healthcare plan with medical and prescription coverage were included.
Results: Of the 6,149,218 patients treated for ADHD, 20,062 received SDX/d-MPH. The mean age of patients treated with SDX/d-MPH was 17 years; the mean age of all treated patients was 24 years. Patients receiving SDX/d-MPH had lower concomitant use of a short-acting (SA) supplementation within 6 months of stabilization on treatment compared with amphetamine long-acting (LA) (12.1 versus 19.5 mean days, P < .001) and methylphenidate LA (12.1 versus 19.9 mean days, P < .001). Patients receiving SDX/d-MPH had a higher rate of concomitant SA use compared with other branded ADHD treatments (lisdexamfetamine: 11% versus 8%, P=.37; dexmethylphenidate XR: 10% versus 6%, P=.03). Patients receiving SDX/d-MPH remained on SA for less time versus lisdexamfetamine (114 versus 125 mean days) or dexmethylphenidate XR (115 versus 129 mean days).
Conclusion: Patients with ADHD using SDX/d-MPH had lower concomitant SA use compared with amphetamine LA and methylphenidate LA and higher rates of concomitant SA use for shorter periods when compared with lisdexamfetamine or dexmethylphenidate XR.
